流式细胞术双标记法检测实体肿瘤DNA含量、细胞周期及Ki67表达

研究主要利用流式细胞术DNA/Ki67双标记法同时检测恶性实体肿瘤细胞的DNA含量、细胞周期和Ki67的表达和周期分布,并探索其相互之间和与病理组织学分级的关系.     

Ki67在鼻咽癌中的表达及意义

 目的　观察Ki6 7在鼻咽癌中的表达及其与鼻咽癌生物学行为和预后的关系。方法　应用SP免疫组化染色法检测鼻咽癌患者放疗前活检组织石蜡标本中Ki6 7在鼻咽癌中的表达情况。结果　 5 6例鼻咽癌标本中 ,Ki6 7阳性表达范围为 0～ 31% ,其中高表达者 16例 ,低表达者 4 0例 (含 14例阴性 )。Ki6 7高表达者 ,对射线敏感 ,预后较好 ;反之 ,对射线不敏感 ,预后较差。结论　Ki6 7可作为评估鼻咽癌患者放射敏感性、预测预后的独立指标之一。     

Ki67与卵巢肿瘤的研究进展

细胞的增殖与肿瘤的发生、浸润及转移过程密切相关，评价细胞的增殖状态对研究肿瘤的生物学行为，判断其危害性，具有重要意义。Ki67是一种增殖细胞相关的核抗原，是近年来研究最多，最具有前途的细胞增生标记。     

Ki67与卵巢肿瘤的研究进展

细胞的增殖与肿瘤的发生、浸润及转移过程密切相关,评价细胞的增殖状态对研究肿瘤的生物学行为,判断其危害性,具有重要意义.Ki67 是一种增殖细胞相关的核抗原,是近年来研究最多,最具有前途的细胞增生标记.     

流式细胞术在实体肿瘤临床中的应用

流式细胞仪在实体肿瘤中广泛应用。应用流式细胞仪可检测实体瘤患者的外周血中各种淋巴细胞、表面细胞因子受体及细胞内细胞因子的表达，监测放化疗前后免疫功能的变化、对造血功能的影响，检测多药耐药基因表达产物及在造血干细胞移植中的应用等。     

PTEN、Ki67在卵巢恶性肿瘤组织中的研究进展

原癌基因的激活、抑癌基因的失活是细胞癌变的基础。本文就抑癌基因PTEN和癌基因Ki67的特点及其细胞周期调控作用与卵巢恶性肿瘤的关系行进综述,并对其研究前景作一展望。     

PTEN、Ki67在卵巢恶性肿瘤组织中的研究进展

原癌基因的激活、抑癌基因的失活是细胞癌变的基础。本文就抑癌基因PTEN和癌基因Ki67的特点及其细胞周期调控作用与卵巢恶性肿瘤的关系行进综述,并对其研究前景作一展望。     

胃肠道间质瘤40例Ki-67、PCNA的表达及意义

目的：探讨Ki-67、PCNA的表达与胃肠道间质瘤（GIST）临床病理特征的关系。方法：应用免疫组化SP法检测40例胃肠道间质瘤中Ki-67、PCNA的表达。结果：40例胃肠道间质瘤中Ki-67、PCNA阳性表达率分别为60．0％、65．0％。Ki-67、PCNA表达与GIsT的性别、年龄、部位、组织学分型无关,与肿瘤大小、组织学分级有关。Ki-67、PCNA的表达呈正相关。结论：Ki-67、PCNA联合检测可作为判定GIST良恶性、恶性程度、肿瘤分级及预后的重要指标。     

细胞核增殖相关抗原Ki67在子宫内膜病变中的表达

目的：研究Ki67抗原在子宫内膜病变中表达的规律及其在子宫内膜癌的发生和预后评估的临床价值。方法：用免疫组化（SP）法检测子宫内膜增殖症及非典型增生各30例，子宫内膜癌90例；对照组30例，其中包括增生期及分泌期子宫内膜各15例，观察Ki67抗原在不同内膜病变及正常内膜中的阳性表达率。结果：Ki67抗原在分泌期内膜中几乎没有表达，在增生期内膜中有弱表达；在增殖症及非典型增生中有表达，但与对照组比较，无统计学意义（P〉0．05），且两者之间比较，亦无统计学意义（P〉0．05）；在子宫内膜癌组织中表达明显增高，显著高于良性病变组和对照组（P〈0．01）。而且Ki67抗原的阳性率随着临床分期及细胞分化级别的升高及淋巴转移的存在而增加。结论：Ki67抗原与子宫内膜癌发生密切相关．抗原过度表达提示子宫内膜癌患者预后不良。     

Smac 和Ki67 在胃癌组织中的表达及其临床意义

 目的 观察Smac和Ki67在胃癌中的表达，并探讨Smac表达与Ki67的关系及其临床意义。方法 应用免疫组织化学法检测71例胃癌组织中Smac和Ki67的表达，分析Smac表达与临床病理因素、预后及Ki67的关系。结果 Smac在胃癌组织中的表达率为71．8％（51／71），在所有的癌旁组织中均见表达（20／20）。Ki67在胃癌组织中表达阳性率为66．2％（47／71）。Smac表达和Ki67表达与胃癌分化程度、浸润深度、淋巴结转移、TNM分期明显相关（Pd0．05）。Ki67在Smac表达阴性的胃癌组织的阳性率（17／20）明显高于Smac表达阳性组（30／51，Pd0．05）。Smac表达阳性患者的生存时间明显长于Smac表达阴性患者（Pd0．05）。结论 Smac和Ki67可作为判断胃癌组织恶性程度和预后的指标之一，其中Smac的表达与Ki67的表达呈负相关。     

Prognostic Significance of the Ki67 Scoring Categories in Breast Cancer Subgroups

BackgroundImmunohistochemical (IHC) expression of Ki67 has a prognostic and predictive value for breast cancer, and the IHC Ki67 labeling index is estimated by counting the number of positive and negative cells. It has not been clarified whether IHC Ki67 estimated using a semiquantitative scoring system has a prognostic value. We aimed to estimate the usefulness of scoring categories of IHC Ki67 as a prognostic factor for breast cancer subgroups.Patients and MethodsWe retrospectively identified patients in the Tokai University breast cancer database for whom IHC Ki67 data were available between January 1, 2000 and December 31, 2010. Survival curves were calculated using the Kaplan-Meier method and compared using the log-rank test.ResultsOf the 1331 primary breast cancer patients included in the study, In patients with estrogen receptor (ER)-positive and HER2-negative tumors (n = 971), high and intermediate Ki67 scores were associated with poorer relapse-free survival than low Ki67 scores (P < .001 and P = .002, respectively). Furthermore, in the multivariate analyses of this subgroup, progression-free survival (PFS) was significantly longer in patients with low Ki67 scores than in patients with high Ki67 scores (hazard ratio, 0.387; 95% confidence interval, 0.233-0.643; P < .001). In the multivariate analyses, the Ki67 score was not significantly associated with PFS in the ER-positive and HER2-positive, ER-negative and HER2-positive, or ER-negative and HER2-negative subgroups.ConclusionOur data demonstrated that low, intermediate, and high Ki67 scores have a prognostic value in breast cancer patients with ER-positive and HER2-negative tumors.     

表皮生长因子受体EGFR和Ki67在非小细胞肺癌中的表达及其相关性研究

目的 :探讨表皮生长因子受体 (epi dermalgrowthfactorreceptor ,EGFR)和Ki67在非小细胞肺癌 (non smallcelllungcancer,NSCLC)中的表达及其与NSCLC发生、发展及预后的关系。方法 :对经随访资料完整的术后NSCLC组织标本 60例、癌旁组织 2 0例和肺正常组织 5例 ,采用SP免疫组化法检测EGFR和Ki67。对术后辅助性化疗 3 6例 ,分析疗效与EGFR和Ki67表达的关系。结果 :NSCLC中EGFR表达阳性率为 65 % ,阳性细胞的棕黄色颗粒位于细胞质 ;Ki67表达阳性率为 81 67% ,阳性细胞的棕黄色颗粒位于细胞核 ;2 0例癌旁组织及 5例正常肺组织未见阳性染色细胞。癌组织EGFR和Ki67表达与癌旁组织相比差异有统计学意义 ,P <0 0 1。NSCLC中EGFR和Ki67阳性表达与年龄、性别、吸烟与否、肿瘤细胞的病理类型差异无统计学意义 ,P >0 0 5 ;与肿瘤大小、病理分级、淋巴结转移和TNM分期密切相关 ,P <0 0 5。EGFR和Ki67表达阳性者 3年生存率分别为19 86%和 3 1 3 3 % ,低于阴性表达 70 11%和90 91% ,P <0 0 5 ;接受术后辅助性化疗的患者 ,EGFR和Ki67阳性表达复发转移率分别为 70 3 7%和 62 5 0 % ,高于阴性表达 11 11%和 0 ,P <0 0 5。结论 :EGFR和Ki67在NSCLC中的异常或过度表达与肿瘤发生、发展密切相关 ,两者表达具有协同作     

Ki67、增殖细胞核抗原在不同分子分型乳腺癌组织中的表达及意义

目的探讨Ki67、增殖细胞核抗原（PCNA）在不同分子类型乳腺癌组织中的表达及临床意义。方法采用免疫组化法检测251例乳腺癌组织中Ki67、PCNA的表达情况,采用kruskal—wallis秩和检验分析Ki67、PCNA在不同分子类型乳腺癌组织中的表达差异;采用Spearman相关分析法,分析不同分子类型中Ki67与PCNA表达的相关性及其分别与原发肿瘤直径、腋窝淋巴结转移及病理组织学分级的相关性;采用生存分析法,分析Ki67、PCNA对乳腺癌预后的意义。结果Luminal型、HER-2型及三阴性乳腺癌组织中Ki67、PCNA表达强度差异均无统计学意义（X^2=3．722,P=0．155;）（X^2=5．135,P=0．077）。Ki67与PCNA总体呈正相关（r1=0．348,P=0．000）,在Luminal型中呈正相关（r3=0．467,P=0．000）,而在HER-2型、三阴性乳腺癌中无相关性（P〉0．05）。Ki67表达强度与原发肿瘤直径、腋窝淋巴结转移及组织学分级在Luminal型乳腺癌呈正相关性（r1=0．180,P：0．017;rs=0．236,P=0．002;0=0．156,P=0．039）,而在HER-2型及三阴性乳腺癌中无相关性（P〉0．05）。PCNA表达强度与Luminal型乳腺癌的腋窝淋巴结转移呈正相关性（r1=0．166,P=0．028）,与HER-2型乳腺癌的原发肿瘤直径呈负相关性（r1=-0．342,P=0．020）,与其他病理因素均无相关性（P〉0．05）。单因素生存分析显示腋窝淋巴结转移、组织学分级对乳腺癌患者无瘤生存有影响（HR=4．431,95％CI：1．787～10．984;HR=2．492,95％C,：1．032～6．018）,亚组分析显示腋窝淋巴结、PCNA对Luminal型乳腺癌患者无瘤生存有影响（HR=3．930,95％C1：1．343～11．501;HR=2．401,95％C1：1．044—5．524）。多因素COX回归分析显示腋窝淋巴结转移是总体和Luminal型乳腺癌患者预后的独立影响因素（HR=3．780,95％CI：1．461—9．775;HR=3．403,95％CI：1．150～10．075）。结论Ki67和PCNA对评估Luminal型乳腺癌预后有一定指导意义,而对HER-2型和三阴性乳腺癌预后无明显影响。     

细胞周期素D1、Ki—67与鼻咽癌

细胞周期素D1（CyclinD1)是细胞周期G1期的重要调控因子之一，它在多种癌组织中扩增和过表达，Ki-67是一种细胞增殖核抗原，广泛应用于评估肿瘤细胞持增殖活性。多数学者认为二者的表达高低与肿瘤的组织类型、分化程度及预后有关，可根据二者的表达情况选择不同的治疗手段、预测放射敏感性及改善预后，但也有学者持相反的观点，本文主要综述二者与鼻咽癌的关系及意义。     

Prognostic impact of Deoxyribonucleic acid (DNA) image analysis cytometry and immunohistochemical expression of Ki67 in surgically resected non-small cell lung cancers

BACKGROUND: The aim of the present study was to evaluate the prognostic significance of DNA ploidy and Ki67 expression in non-small cell lung carcinoma (NSCLC). METHODS: This prospective study included 96 patients with stages I-IIIA NSCLC who underwent surgical excision. DNA image analysis cytometry was applied on imprints. Calculation of the DNA index (DI) and the 5c exceeding rate (5cER) was performed and the histograms were classified as peridiploid, peritetraploid, and x-ploid-multiploid. The Ki67 immunoreactivity was determined according to the avidin-biotin complex immunoperoxidase method. RESULTS: DNA histogram classification disclosed 30 peridiploid cases, 15 peritetraploid and 51 x-ploid-multiploid. Forty-eight cases (50%) had 5cER > 5%. The Ki67 immunoreactivity was below 25% in 53 tumors (62.4%) and above 25% in 32 (32.6%). Our results revealed the existence of a statistically significant relationship of DNA ploidy with nodal status (p = 0.042) and grade (p = 0.005). Adenocarcinomas and large cell carcinomas were more frequently encountered in x-ploid-multiploid tumors as compared to squamous cell carcinomas, which were more frequently peridiploid (p = 0.003). 5cER showed statistically significant association with nodal status (p = 0.037). Univariate analysis with respect to survival revealed significant association with stage (p < 0.001), nodal status (p < 0.001), tumor status (p < 0.001), DNA ploidy (p = 0.008) and 5cER (p = 0.0124). Multivariate analysis revealed stage and ploidy status as independent factors: peridiploid tumors were associated with better survival as compared to x-ploid-multiploid tumors (p = 0.022). CONCLUSION: Our results suggest that DNA ploidy, as determined by image analysis, provides an independent prognostic parameter for patients with NSCLC and thus, could be used to identify a subset of patients with more aggressive tumors.     

FHIT、Ki67和bax在宫颈癌中的表达及临床意义

 目的　观察FHIT、Ki6 7和bax在宫颈癌组织中的表达情况 ,探讨FHIT、Ki6 7和bax与宫颈癌临床病理指标及预后之间的关系。方法　应用免疫组化方法检测 5 0例宫颈癌和 2 0例正常宫颈组织中FHIT、Ki6 7和bax蛋白的表达。结果　 5 0例宫颈癌中 ,2 6例 (5 2 % )显示FHIT蛋白表达降低或缺失 ,36例 (72 % )Ki6 7表达阳性 ,31例 (6 2 % )bax表达阳性。FHIT表达的降低或缺失不仅与肿瘤的高分级(P =0 .0 0 3)和淋巴结转移 (P =0 .0 0 2 )明显相关 ,而且与宫颈癌的复发和死亡关系密切 (P =0 .0 19)。bax蛋白的表达随病理分级的升高而降低 (P =0 .0 12 )。FHIT蛋白的表达与bax的表达成正相关 (rs=0 .340 ,P =0 .0 16 ) ,与Ki6 7的表达成负相关 (rs=- 0 .2 92 ,P =0 .0 39)。结论　FHIT的异常表达在宫颈癌的发展中起着重要作用 ,而且可为宫颈癌的评估提供重要的预后信息     

Expression of Ki67 in Papillary Thyroid Microcarcinoma and its Clinical Significance

Purpose: To investigate the expression of Ki67 protein in papillary thyroid microcarcinoma(PTMC), and toanalyze its clinical significance. Materials and Methods: Ki67 protein expression was evaluated in the tissues of108 human PTMC and 50 other benign papillary hyperplasia of thyroid specimens using immunohistochemistry.Results: The expression intensity of Ki67 in PTMC and benign papillary hyperplasia of thyroid specimenswere 1.45±1.83% and 0.46±0.46%.The positive expression rates were 46.3% and 14%. There were significantdifferences between these two groups (p<0.01). There was no significant variation of the expression intensityand positive expression rates of Ki67 in PTMC with gender, age, position of the tumor and the level of TSHpre-operation (p>0.05), but these parameters varied with tumor size, invasion by membrane and cervical lymphnode metastasis (p<0.05 or p<0.01). Conclusions: The expression of Ki67 in PTMC was related to tumor size,invasion by membrane and cervical lymph node metastasis, and could be the important indicator for judgingclinical progress and estimating prognosis.